The Fagerström Test for Nicotine Dependence, As a Prognostic Factor, in Current Smokers with and Without COPD: A Cross-sectional Study in Northern Greece

Overview

Journal Chron Respir Dis

Publisher Sage Publications

Date 2024 Mar 13

PMID 38476003

Authors

Efthymia Papadopoulou

Anna-Bettina Haidich

Alexander Mathioudakis

Drosos Tsavlis

Konstantina Papadopoulou

Rena Oikonomidou

Panagiotis Bogiatzidis

Stavros Tryfon

Affiliations

Soon will be listed here.

Abstract

Background: Smoking poses the most common risk factor for chronic obstructive pulmonary disease (COPD) and aggravates disease progression. Tobacco dependence inhibits smoking cessation and may affect smoking patterns that increase tobacco exposure and predispose to lung function decline.

Aims And Objectives: We aimed to assess tobacco dependence in current smokers with and without COPD and evaluate its role in disease development.

Method: This cross-sectional study was conducted in Greek rural areas. Current smokers completed the Fagerström Test for Nicotine Dependence and were classified into COPD and non-COPD groups based on spirometry parameters.

Results: Among current smokers, 288 participants comprised the non-COPD and 71 the COPD group. Both presented moderate tobacco dependence, but smokers with COPD started to smoke earlier in the morning. Multiple logistic regression analysis revealed higher COPD prevalence in smokers with higher scores in the Fagerström test (odds ratio OR = 1.12, 95% confidence interval [1.01 - 1.24]) and older age (OR = 1.06 [1.03 - 1.09]), independently of pack-years smoking index. Multiple linear regression analysis in smokers with COPD showed that the forced expiratory volume in the 1st second decreased by 2.3% of the predicted value for each point increase in the Fagerström Test and 0.59% for each year of age, independently of participants' sex and pack-years smoking index.

Conclusion: The Fagerström score appears to indicate a higher probability for COPD and lung function deterioration when assessed along with age in current smokers. Smoking cessation support programs are fundamental to COPD prevention and management.

References

Agusti A, Celli B, Criner G, Halpin D, Anzueto A, Barnes P . Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. Eur Respir J. 2023; 61(4). PMC: 10066569. DOI: 10.1183/13993003.00239-2023. View

Kim D, Hersh C, Washko G, Hokanson J, Lynch D, Newell J . Epidemiology, radiology, and genetics of nicotine dependence in COPD. Respir Res. 2011; 12:9. PMC: 3033825. DOI: 10.1186/1465-9921-12-9. View

Willemse B, Postma D, Timens W, Ten Hacken N . The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation. Eur Respir J. 2004; 23(3):464-76. DOI: 10.1183/09031936.04.00012704. View

Jimenez-Ruiz C, Masa F, Miravitlles M, Gabriel R, Viejo J, Villasante C . Smoking characteristics: differences in attitudes and dependence between healthy smokers and smokers with COPD. Chest. 2001; 119(5):1365-70. DOI: 10.1378/chest.119.5.1365. View

Benowitz N . Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Annu Rev Pharmacol Toxicol. 2008; 49:57-71. PMC: 2946180. DOI: 10.1146/annurev.pharmtox.48.113006.094742. View

Viniol C, Vogelmeier C . Exacerbations of COPD. Eur Respir Rev. 2018; 27(147). PMC: 9488662. DOI: 10.1183/16000617.0103-2017. View

Liu Y, Greenlund K, VanFrank B, Xu F, Lu H, Croft J . Smoking Cessation Among U.S. Adult Smokers With and Without Chronic Obstructive Pulmonary Disease, 2018. Am J Prev Med. 2022; 62(4):492-502. PMC: 8996345. DOI: 10.1016/j.amepre.2021.12.001. View

Volk R, Mendoza T, Hoover D, Nishi S, Choi N, Bevers T . Reliability of self-reported smoking history and its implications for lung cancer screening. Prev Med Rep. 2020; 17:101037. PMC: 6951268. DOI: 10.1016/j.pmedr.2019.101037. View

Chang J, Meza R, Levy D, Arenberg D, Jeon J . Prediction of COPD risk accounting for time-varying smoking exposures. PLoS One. 2021; 16(3):e0248535. PMC: 7946316. DOI: 10.1371/journal.pone.0248535. View

10.

Pleasants R, Rivera M, Tilley S, Bhatt S . Both Duration and Pack-Years of Tobacco Smoking Should Be Used for Clinical Practice and Research. Ann Am Thorac Soc. 2020; 17(7):804-806. PMC: 7405110. DOI: 10.1513/AnnalsATS.202002-133VP. View

11.

Liu Y, Pleasants R, Croft J, Wheaton A, Heidari K, Malarcher A . Smoking duration, respiratory symptoms, and COPD in adults aged ≥45 years with a smoking history. Int J Chron Obstruct Pulmon Dis. 2015; 10:1409-16. PMC: 4516194. DOI: 10.2147/COPD.S82259. View

12.

von Elm E, Altman D, Egger M, Pocock S, Gotzsche P, Vandenbroucke J . Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007; 335(7624):806-8. PMC: 2034723. DOI: 10.1136/bmj.39335.541782.AD. View

13.

Anthonisen N, Skeans M, Wise R, Manfreda J, Kanner R, Connett J . The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med. 2005; 142(4):233-9. DOI: 10.7326/0003-4819-142-4-200502150-00005. View

14.

Kim E, Yoon S, Kim Y, Go D, Jung Y . Effects of Aging and Smoking Duration on Cigarette Smoke-Induced COPD Severity. J Korean Med Sci. 2019; 34(Suppl 1):e90. PMC: 6434146. DOI: 10.3346/jkms.2019.34.e90. View

15.

Heatherton T, Kozlowski L, Frecker R, Fagerstrom K . The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991; 86(9):1119-27. DOI: 10.1111/j.1360-0443.1991.tb01879.x. View

16.

Guyatt A, Kirkham A, Baldry A, Dixon M, Cumming G . How does puffing behavior alter during the smoking of a single cigarette?. Pharmacol Biochem Behav. 1989; 33(1):189-95. DOI: 10.1016/0091-3057(89)90449-8. View

17.

Pomerleau C, Majchrzak M, Pomerleau O . Nicotine dependence and the Fagerström Tolerance Questionnaire: a brief review. J Subst Abuse. 1989; 1(4):471-7. View

18.

Bazzan E, Semenzato U, Turato G, Biondini D, Cubero P, Marin-Oto M . Symptomatic smokers without COPD have physiological changes heralding the development of COPD. ERJ Open Res. 2022; 8(2). PMC: 9234424. DOI: 10.1183/23120541.00202-2022. View

19.

Graham B, Steenbruggen I, Miller M, Barjaktarevic I, Cooper B, Hall G . Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med. 2019; 200(8):e70-e88. PMC: 6794117. DOI: 10.1164/rccm.201908-1590ST. View

20.

Fagerstrom K, Furberg H . A comparison of the Fagerström Test for Nicotine Dependence and smoking prevalence across countries. Addiction. 2008; 103(5):841-5. PMC: 2914535. DOI: 10.1111/j.1360-0443.2008.02190.x. View